ACTU director granted 15,000 stock options
ACTUATE THERAPEUTICS, INC. director Jason A. Keyes received a grant of stock options covering 15,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ACTUATE THERAPEUTICS, INC. director Jason A. Keyes received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036. According to the footnote, the options will vest in full on the first anniversary of the grant date, meaning Keyes must remain eligible through that date before the award is fully exercisable. Following this grant, his reported derivative holdings from this award total 15,000 stock options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 15,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Options will vest in full on the anniversary of the grant date.
Key Figures
Key Terms
Stock Options financial
Common Stock financial
Grant, award, or other acquisition financial
vest in full financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ACTU director Jason A. Keyes receive in this Form 4 for ACTU?
What is the exercise price of Jason Keyes’ new ACTU stock options?
When do Jason Keyes’ ACTU stock options vest and expire?
How many ACTU stock options does Jason Keyes hold after this transaction?
Is Jason Keyes’ ACTU Form 4 transaction a market purchase or sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.